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Statins are indicated in patients with elevated levels of high-sensitivity C-reactive protein and normal low-density lipo-
protein cholesterol based on results of themulticountry trial, Justification for theUse of Statins in Prevention: an Interven-
tion Trial Evaluating Rosuvastatin (JUPITER) (2003–2008), but the benefit in real-world populations remains unknown.
We sought to generalize JUPITER results to trial-eligible population using data from the UK Clinical Practice Research
Datalink (CPRD), 2001–2014. We multiply imputed missing baseline characteristics for the CPRD population and
selected the trial-eligible participants as the target population based on observed and imputed values. Trial participants
were weighted to be representative of the CPRD population (n = 383,418) based on individual predicted probability
of selection into the trial. Trial participants were also standardized to the CPRD population without missing values
(n = 2,677). In JUPITER, rosuvastatin reduced cardiovascular risk with a 3-year risk difference of −2.0% (95% confi-
dence interval (CI):−2.9,−1.1). The rosuvastatin effect wasmuted in the first 2 years but remained strong at 3 years after
standardizing to the imputedCPRDpopulation (3-year risk difference= −2.7%; 95%CI:−5.8, 0.4) and the CPRD popu-
lationwithoutmissing data (3-year risk difference= −1.7%; 95%CI:−3.5, 0.1). The study serves as an illustration of pos-
sible approaches to understanding generalizability of trials using real-world databases given limitations due to missing
data on inclusion/exclusion criteria.
cardiovascular diseases; generalizability; JUPITER trial; randomized clinical trial; statins
Abbreviations: BMI, body mass index; CI, confidence interval; CPRD, Clinical Practice Research Datalink; CVD, cardiovascular
disease; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; JUPITER, Justification for the
Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL-C, low-density lipoprotein cholesterol; RCT,
randomized clinical trial.
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors) are widely prescribed for the primary prevention of
cardiovascular disease (CVD) (1). Justification for the Use of
Statins in Prevention: an Intervention Trial Evaluating Rosuvas-
tatin (JUPITER) showed that rosuvastatin effectively reduced
the risk of CVD in individuals not at high risk for CVD because
of elevated low-density lipoprotein cholesterol (LDL-C) but
with elevated levels of high-sensitivity C-reactive protein (hs-
CRP) (2). As a well-designed and properly conducted random-
ized clinical trial (RCT), JUPITER has strong internal validity.
However, the external validity of the JUPITER trial has been
called into question because the subjects enrolled in the
JUPITER trial may not represent the real-world population of
interest (3). The heterogeneous effect of rosuvastatin in the
JUPITER trial (4–6) and the general selection of trial partici-
pants would need to be taken into account when generalizing
the expected benefit of rosuvastatin to a representative population
of real-world patients whomeet JUPITER inclusion criteria.
To generalize RCT results to real-world populations, we
need to standardize the distribution of factors affecting treatment
efficacy in the RCT population to that observed in the real-
world population. With multiple effect modifiers, standard-
ization quickly becomes intractable. Cole and Stuart (7) therefore
proposed a weighting approach based on predicting the
individual probability of being in the trial versus the target
population as a function of multiple factors and to reweight
the RCT participants to be representative of the target pop-
ulation. This idea is a generalization of the same concept
as propensity score weighting to control for confounding
(8, 9).
While compelling in theory, in practice, data on RCT
inclusion/exclusion criteria and effect modifiers are likely to be
missing in a portion of the target population, because mea-
sures for systemic inflammation (such as hs-CRP) and for
chronic kidney disease are not routinely recorded in existing
real-world data. Physicians are more likely to order these tests
for patients at higher risks for CVD. This leads to a selection
of the study population representing the target population.
Ignoring individuals in the target population with missing val-
ues on effect modifiers could thus result in the wrong target
population.
The objective of this study was to estimate the effect of ro-
suvastatin initiation on the risk of CVD events in the UK pop-
ulation who would have been eligible for the JUPITER trial,
as represented in the Clinical Practice Research Datalink
(CPRD) population (10), by generalizing the results of the
JUPITER trial to the target population and addressing both
selection into the trial and issues related to the identification
of a study population that represents the target population.
METHODS
Study population
The JUPITER trial (ClinicalTrials.gov identifier:NCT00239681)
was a randomized, double-blind, placebo-controlled trial of
rosuvastatin (20 mg daily) for the primary prevention of CVD
events, enrolling 17,802 patientswith subclinical systemic inflam-
mation but without hypercholesterolemia from 26 countries
between 2003 and 2008 (2). Briefly, eligible patients were men
aged ≥50 years or women aged ≥60 years who had elevated
hs-CRP levels but did not have hyperlipidemia (i.e., hs-CRP
≥2.0 mg/L, LDL-C<130 mg/dL, and triglycerides<500 mg/dL).
The exclusion criteria included a history of CVD, diabetes, and
cancer. The primary endpoint was the occurrence of a first major
CVD event, defined as nonfatal myocardial infarction, nonfatal
stroke, hospitalization for unstable angina, arterial revasculariza-
tion procedure, or confirmed death from cardiovascular causes.
The target population that we chose in this study consisted of
patients in the CPRD who would have been eligible to partici-
pate in the JUPITER trial. The concept of the algorithm used to
identify the eligible patients is described as follows and in Web
Figure 1 (available at https://academic.oup.com/aje). The flow
chart of study cohort selection is included inWeb Figure 2.
We selected all men aged ≥50 years and women aged ≥60
years with ≥2 years of registration with a general practitioner
after the practice came “Up-to-Standard” (i.e., the practice data
met the CPRD’s quality criteria), during the study period from
January 1, 2001, throughDecember 31, 2014. The date ofmeet-
ing both age and registration-time requirements was defined as
cohort entry date. Patients were required to have no history of
CVD, diabetes, or cancer and to have received no prescriptions
of any lipid-lowering drugs before or on the cohort entry date.
CVD and cancer events were defined as 1 diagnosis Read code,
and diabetes was defined by a diagnosis Read code, receipt of
any antihyperglycemic drug, or abnormal glucose or hemo-
globin A1C test results (fasting plasma glucose ≥7.0 mmol/L
or hemoglobin A1C of ≥6.5%). The eligibility time period was
defined from the cohort entry date to the earliest date of the fol-
lowing events: diagnosis of CVD, diabetes, or cancer (except
for basal-cell or squamous-cell carcinoma of the skin); initiation
of any lipid-lowering agents; death; the last day of data collec-
tion from the general practice; migration out of the general prac-
tice; or the end of study (December 31, 2014). For each patient,
we randomly selected an index date from all the dates of general
practitioner visits within the eligibility time period. General
practitioner visit was defined as having a medical record with
consultation types of Clinic or Surgery Consultation visit
from the Clinical Table in the CPRD.
Covariates andmissing data
In the CPRD, the baseline characteristics and laboratory
measurements were assessed for each patient, using data
within 24months prior to the index date, including demographic
information, body mass index (BMI), tobacco smoking status,
laboratory tests, medical history, medication use, and indicators
of health-care use. To account for possible data-entry errors in
the CPRD and JUPITER, we applied trimming rules for all lab-
oratory tests andmeasurement results, and wemade further con-
siderations for hs-CRP values given that underlying hs-CRP
values could be masked by infection, both of which we outline
in detail inWebAppendix 1.
We imputed missing baseline characteristics and laboratory
measurements among the eligible CPRD patients, using multi-
ple imputation (11–15). Multiple imputation relies on the
assumption that data are missing at random. This means, for
example, that missingness of hs-CRP may depend on observed
patient characteristics but does not depend on the (unknown)
actual value of the hs-CRP or other unobserved data within
strata of measured predictors. We used a multivariate normal
imputationmodel fit byMarkov ChainMonte Carlo simulation
to impute all missing data in 20 imputed data sets. Each imputed
data set was then analyzed separately, and the results from the
20 analyses were combined using Rubin’s formula to give over-
all estimates while accounting for the variability across the
imputed data sets (14).
After imputing missing baseline characteristics for all CPRD
patients, we selected the patients who satisfied the trial criteria
based on actual or imputed values (e.g., LDL-C value of <130
mg/dL, hs-CRP value of ≥2.0 mg/L, and triglyceride value of
<500 mg/dL) in each imputed data set. These cohorts were
called the imputed cohorts, the main study populations to repre-
sent the target. To assess the potential selection of the target
population due to missing values, we examined another study
population consisting of patients with complete data only.
From all eligible CPRD patients, we selected only patients who
had complete data on BMI, smoking status, LDL-C, high-density
lipoprotein cholesterol (HDL-C), triglycerides, total cholesterol,
systolic and diastolic blood pressure, hs-CRP, serum creatinine,
and glucose at the index date and then included those who met
the inclusion criteria of the JUPITER trial based on actual
laboratory measurements. Following the usual terminology in
and target populations. Next, we used the standardized mortal-
ity or morbidity ratio method to assign selection weights to
each JUPITER trial participant depending on their individual
characteristics. These selection weights were calculated as the
odds of 1 minus the predicted probability of selection into the
trial and scaled by multiplying with the (marginal) odds of
being in the trial (9).Within the reweighted JUPITER trial, we
then used Cox proportional hazard models (with robust vari-
ance estimator) to estimate hazard ratios and their 95% confi-
dence intervals for the comparison of major cardiovascular
events between those randomized to rosuvastatin versus pla-
cebo. We calculated the weighted risk difference using a non-
parametric method accounting for non-CVD competing causes
of death, and we obtained standard deviations from 200 boot-
strap data sets to calculate 95% confidence intervals (16). To
Table 1. Baseline Characteristics Before and After Multiply Imputing Missing Values Among Clinical Practice
Research Datalink Participants (United Kingdom, 2001–2014) Before Applying the Inclusion/Exclusion Criteria for
“Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin” (Multiple Countries,
2003–2008)
Variablea
Original CPRD Population (n = 1,438,355) After Multiple Imputationb,c
Distribution Missing Distribution
% Median (IQR) % % Median (IQR)
Age, years 63 (57–72) 0 63 (57–72)
Male sex 57.6 0 57.6
BMId 26.8 (23.9–30.3) 57.6 26.7 (23.6–30.1)
Current smoker 21.0 35.2 18.0
hs-CRP, mg/L 4.0 (2.0–7.0) 88.2 3.8 (2.0–6.8)
DBP, mmHg 80 (74–87) 23.3 80 (74–87)
SBP, mmHg 139 (128–149) 23.3 138 (127–149)
HDL-C, mg/dL 54 (46–66) 65.1 56 (46–68)
LDL-C, mg/dL 135 (112–159) 70.0 135 (112–159)
Triglycerides, mg/dL 124 (91–169) 68.2 121 (89–168)
Total cholesterol, mg/dL 218 (193–244) 57.8 219 (193–245)
Glucose, mmol/L 5.1 (4.8–5.6) 87.1 5.3 (4.6–6.0)
SerumCreatinine, mg/dL 1.0 (0.8–1.1) 45.6 1.0 (0.8–1.1)
Abbreviations: BMI, body mass index; CPRD, Clinical Practice Research Datalink; DBP, diastolic blood pressure;
HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C reactive protein; IQR, interquartile range;
JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL-C, low-
density lipoprotein cholesterol; SBP, systolic blood pressure.
a The variables chosen for multiple imputation and for the model of selection into the trial were based on their high rele-
vance to cardiovascular diseases. Several laboratory tests were used in the exclusion criteria of JUPITER but were not
selected here because of largemissingness in theCPRDand not being strong predictors for cardiovascular disease.
b The distributions of the variables were very similar across the 20 imputed data sets. Thus, we presented the re-
sults from a randomly selected imputed data set in the table.
c The imputation model included the following variables: age, male sex, BMI, weight within 2 years prior to the index
date, previous weight recorded before 2 years before the index date, tobacco smoking status within 2 years prior to
the index date, prior smoking status recorded before 2 years before the index date, diagnosis related to smoking,
smoking cessation prescriptions, diagnosis of alcohol abuse, DBP, SBP, LDL-C, HDL-C, log transformation of trigly-
cerides, total cholesterol, log transformation of hs-CRP, glucose, serum creatinine, use of any nonsteroidal antiinflam-
matory drugs, use of angiotensin-converting-enzyme inhibitor, use of angiotensin II receptor blockers, use of beta
blockers, use of loop or nonloop diuretics, use of calcium channel blockers, diagnosis of renal disease, calendar year,
and number of general practitioner encounters. In addition, occurrence of major cardiovascular disease and rosuvas-
tatin initiation were prospectively assessed within 2 years after the index date and were included in the multiple impu-
tationmodel to improve the performance of imputation.
d Weight (kg)/height (m)2.
missing data settings, we refer to this selected study popula-
tion as the complete case cohort.
Statistical analysis
To generalize the JUPITER trial results to the target popula-
tion, we estimated the probability of selection into JUPITER 
by combining JUPITER and the target population into a single 
data set. Given the large size of the JUPITER trial and the tar-
get population, we estimated the probability of selection into 
JUPITER using a logistic regression model that included all 
factors potentially affecting selection and higher-order prod-
uct terms for the joint distribution (7). The higher-order and 
interaction terms included in the logistic model were selected 
to achieve marginal balance of covariates between the trial
Table 2. Baseline Characteristics Before and After SelectionWeightinga,b Among the Imputed Cohort From the Clinical Practice Research Datalink (United Kingdom, 2001–2014) and the










Group (n = 8,015)
Weighted Placebo Group
(n = 8,150)
% Median (IQR) % Median (IQR) % Median (IQR) % Median (IQR) % Median (IQR)
Age, years 64 (57–74) 66 (60–71) 65 (57–74) 65 (57–74) 64 (57–74)
Male sex 64.1 61.8 63.3 63.2 63.4
BMIe 26.6 (23.5–30.1) 28.3 (25.3–32.0) 26.5 (23.6–29.8) 26.6 (23.6–30.0) 26.5 (23.6–29.7)
Current smoker 20.3 15.8 20.5 20.3 20.7
Antihypertensive drugs 38.8 49.7 39.9 39.9 39.9
Aspirin 9.4 18.6 9.5 9.0 10.1
Moderate CKDf 28.8 18.3 26.3 26.9 25.7
hs-CRP, mg/L 4.8 (3.1–7.6) 4.1 (2.8–6.5) 4.8 (3.1–7.7) 4.8 (3.1–7.6) 4.8 (3.1–7.7)
DBP, mmHg 80 (74–86) 80 (75–87) 80 (73–86) 80 (74–87) 80 (73–86)
SBP, mmHg 138 (126–147) 134 (124–145) 138 (127–150) 139 (128–150) 136 (126–148)
HDL-C, mg/dL 56 (45–68) 49 (40–60) 57 (45–68) 57 (45–69) 56 (45–68)
LDL-C, mg/dL 109 (93–120) 108 (94–119) 109 (93–120) 108 (93–120) 109 (92–120)
Triglycerides, mg/dL 115 (83–159) 118 (85–169) 113 (81–161) 114 (80–158) 113 (82–163)
Total cholesterol, mg/dL 189 (172–206) 185 (169–200) 190 (172–206) 191 (173–206) 190 (172–205)
Glucose, mmol/L 5.2 (4.6–5.8) 5.2 (4.8–5.7) 5.2 (4.8–5.6) 5.1 (4.8–5.6) 5.2 (4.8–5.6)
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CPRD, Clinical Practice Research Datalink; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate;
HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C reactive protein; IQR, interquartile range; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
a Weights were truncated at 20.We chose our truncation weight of 20 based on comparing the distribution of covariates between the trial-eligible CPRD population and the weighted trial pop-
ulation as well as the variance of the treatment effect estimate across various levels of truncation. The results without weight truncation are presented inWeb Table 4.
b The logistic regression model used to predict the probability of being selected in the imputed cohort included the following variables: age, age2, age3, age4, age5, male, male × age, male ×
age2, male × age3, male × age4, smoker, smoker × age, smoker × male, CKD, CKD × male, CKD × age, CKD × age2, CKD × age3, antihypertensive drugs, antihypertensive drugs × age, anti-
hypertensive drugs × age2, antihypertensive drugs × male, antihypertensive drugs × CKD, aspirin, age × aspirin, age2 × aspirin, aspirin × antihypertensive drugs, BMI, BMI2, BMI × CKD, BMI
× smoker, BMI ×male, BMI2 ×male, hsCRP, hsCRP2, hsCRP3, hsCRP4, hsCRP × smoker, hsCRP ×male, hsCRP2 ×male, hsCRP3 ×male, DBP, DBP × SBP, SBP, SBP2, SBP3, SBP × CKD,
SBP2 × CKD, SBP3 × CKD, SBP × antihypertensive drugs, SBP2 × antihypertensive drugs, SBP3 × antihypertensive drugs, HDL-C, HDL-C2, HDL-C3, HDL-C4, HDL-C5,HDL-C × CKD, HDL-C ×
smoker, HDL-C ×male, LDL-C, LDL-C2, LDL-C3, LDL-C4, glucose, glucose × antihypertensive drugs, glucose × BMI, glucose × age, glucose × age2, glucose × LDL-C, log(triglycerides), log(tri-
glycerides)2, log(triglycerides)3, log(triglycerides) × HDL-C, and total cholesterol.
c We multiply imputed 20 data sets. We used one randomly selected imputed data set to select variables included in the selection model and to examine balance in baseline characteristics
between the target population and JUPITER. Thus, we presented the results from this randomly selected imputed data set in the table.
d Absolute standardized differences in baseline characteristics between the weighted JUPITER trial and the target population are presented inWeb Table 5 and were less than 5%.We calcu-
lated absolute standardized differences using SAS (SAS Institute, Inc.) Macro stddiff% (29).
eWeight (kg)/height (m)2.
f Moderate CKD was defined as the eGFR <60 mL/minute/1.73 m2. eGFR was calculated using serum creatinine values and the Modification of Diet in Renal Disease Study equation. Pa-
tients on dialysis or with eGFR<15 mL/minute/1.73 m2 were excluded from the study population.
Table 3. Baseline Characteristics Before and After SelectionWeightinga,b Among the Complete Case Cohort From the Clinical Practice Research Datalink (United Kingdom, 2001–2014) and





Original Trial (n = 17,802) Weighted Trialc (n = 16,235) Weighted RosuvastatinGroup (n = 8,069)
Weighted Placebo
Group (n = 8,166)
% Median (IQR) % Median (IQR) % Median (IQR) % Median (IQR) % Median (IQR)
Age, years 63 (58–71) 66 (60–71) 63 (58–70) 64 (58–70) 63 (58–70)
Male sex 57.9 61.8 58.3 57.6 59.0
BMId 28.4 (24.9–32.3) 28.3 (25.3–32.0) 28.3 (25.2–32.0) 28.3 (25.2–32.0) 28.4 (25.2–32.0)
Current smoker 16.9 15.8 16.9 17.6 16.3
Antihypertensive drugs 56.6 49.7 56.7 56.3 57.1
Aspirin 12.0 18.6 12.2 12.0 12.4
Moderate CKDe 21.2 18.3 21.1 21.2 20.9
hs-CRP, mg/L 5.0 (3.0–7.0) 4.1 (2.8–6.5) 4.9 (3.0–7.3) 4.9 (3.0–7.3) 4.9 (3.0–7.3)
DBP, mmHg 80 (73–85) 80 (75–87) 80 (73–86) 80 (73–86) 80 (73–86)
SBP, mmHg 136 (125–144) 134 (124–145) 135 (126–145) 135 (126–146) 134 (125–145)
HDL-C, mg/dL 51 (43–62) 49 (40–60) 51 (42–62) 51 (42–63) 50 (42–62)
LDL-C, mg/dL 112 (101–120) 108 (94–119) 112 (99–121) 112 (99–122) 112 (99–121)
Triglycerides, mg/dL 126 (104–168) 118 (85–169) 125 (105–166) 125 (106–165) 125 (105–168)
Total cholesterol, mg/dL 191 (178–205) 185 (169–200) 192 (177–206) 193 (178–206) 191 (176–205)
Glucose, mmol/L 5.1 (4.8–5.5) 5.2 (4.8–5.7) 5.2 (4.8–5.6) 5.2 (4.8–5.6) 5.2 (4.8–5.6)
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CPRD, Clinical Practice Research Datalink; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate;
HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C reactive protein; IQR, interquartile range; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
a Weights were truncated at 20.We chose our truncation weight of 20 based on comparing the distribution of covariates between the trial-eligible CPRD population and the weighted trial pop-
ulation as well as the variance of the treatment effect estimate across various levels of truncation. The results without weight truncation are presented inWeb Table 6.
b The logistic regression model used to predict the probability of being selected in the complete case cohort included the following variables: age, age2, male, male × age, male × age2,
smoker, smoker × age, smoker ×male, CKD, CKD × male, CKD × age, CKD × age2, antihypertensive drugs, aspirin, aspirin × antihypertensive drugs, BMI, BMI2, hsCRP, hsCRP2, hsCRP3,
hsCRP4, hsCRP5, hsCRP6, hsCRP7, DBP, SBP, SBP2, SBP3, SBP × antihypertensive drugs, HDL-C, HDL-C × smoker, LDL-C, LDL-C ×male, glucose, log(triglycerides), log(triglycerides)2,
log(triglycerides)3, log(triglycerides)4, and total cholesterol.
c Absolute standardized differences in baseline characteristics between the weighted JUPITER trial and the target population are presented inWeb Table 7 and were less than 5%.We calcu-
lated absolute standardized differences using SAS (SAS Institute, Inc.) Macro stddiff% (29).
dWeight (kg)/height (m)2.
e Moderate CKD was defined as the eGFR <60 mL/minute/1.73 m2. eGFR was calculated using serum creatinine values and the Modification of Diet in Renal Disease Study equation. Pa-
tients on dialysis or with eGFR<15 mL/minute/1.73 m2 were excluded from the study population.
reduce the influence of large weights and to increase the
precision of the estimate, we implemented weight trunca-
tion of predicted probabilities (17). Because only 806 of
JUPITER participants were aged 80 years or older, we also
reestimated the generalized treatment effect among patients
less than 80 years of age.
All statistical analyses were performed with SAS, version 9.3
(SAS Institute, Inc., Cary, North Carolina). This study was
approved by the Institutional Review Board at the University of
North Carolina at Chapel Hill and by the Independent Scientific
Advisory Committee for Medicines and Healthcare products
Regulatory Agency database research in the United Kingdom.
RESULTS
In the CPRD, we identified a total of 1,438,355 men aged
≥50 years and women aged ≥60 years who had no medical
history of diabetes, cancer, or CVD at cohort entry. As expected,
many patients had missing data for BMI, smoking status, and
relevant laboratory tests (Table 1). Blood pressure was the
best recorded variable, with 23%missing, followed by smoking
status, with 35% missing. Fifty-eight percent of patients had
missing BMI and 58%–70% hadmissing cholesterol data. Val-
ues for hs-CRP were missing in 88%. After imputing missing
data, the proportion of individuals identified as current smo-
kers decreased from 21% to 18%, but the distribution of all
other variables was comparable with data before imputation.
Among these approximately 1.4 million CPRD patients, only
10,271 (0.7%) patients had complete data on BMI, smoking
status, and all relevant laboratory tests.
After imputing missing data, a total of 383,418 patients (27%
of the initial cohort) would have been eligible for the JUPITER
trial. Table 2 presents the baseline characteristics of the imputed
cohort and the JUPITER trial participants. Compared with the
imputed cohort, the JUPITER trial participants tended to have
higher BMI but lower hs-CRP and HDL-C levels, and they were
more likely to receive aspirin and antihypertensive drugs, to be
female, and to be free ofmoderate chronic kidney disease. As ex-
pected, the baseline characteristics of the weighted trial partici-
pants were very similar to that of the imputed cohort. Also
expected, weighting did not affect randomization, as demonstrated
by similar covariate distributions in the weighted rosuvastatin and
placebo arms.
Among the 10,271 CPRD patients with complete data on all
relevant variables, 2,677 (26%) patients would have been eligible
to participate in the trial. Comparedwith the imputed cohort, indi-
viduals in the complete case cohort were less likely to be male, to
be current smokers, or to have moderate chronic kidney disease.
The patients in the complete case cohort were also more likely to
receive antihypertensive drugs or aspirin and to have higher BMI
and worse lipid levels. Web Figure 3 presents visualized com-
parison for baseline characteristics among the JUPITER trial
and two target populations. Table 3 compares the baseline
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Figure 1. Treatment effect (hazard ratio (HR) and 95% confidence interval (CI)) of rosuvastatin in the multiple-country trial, Justification for the Use
of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) (2003–2008), before and after standardizing to the imputed cohort
and the complete case cohort with selection weight truncated at 20. For the results from JUPITER standardized to the imputed cohort, the hazard
ratios were first estimated in JUPITER standardized to each imputed data set (Web Table 8) and then combined into overall estimates to account for
variability.
eligible to be enrolled in the trial was possible and led to a finding
of slightly attenuated but still beneficial effects of rosuvastatin on
primary prevention of CVD in patients without hyperlipidemia.
Reweighting the trial population allowed us to estimate a more
realistic treatment effect in the target population while still
benefitting from the advantages of randomization.
Our generalized estimate is still based on the trial population,
including any effect of the trial on adherence and persistence—
what is often referred to as efficacy rather than effectiveness. The
only difference between the original trial result and our general-
ized trial result is that wemade the trial population similar to the
target population by upweighting individuals less likely to be
enrolled. We did so by implementing weighting methods that
are widely used to achieve marginal balance of characteristics
across treatment cohorts for confounding control (i.e., propen-
sity scores) (18, 19). Thesemethods are infrequently used, how-
ever, in other settings, including for generalizing trial results.
While relying on simple principles and statistical techniques,




Figure 2. Cumulative incidences of the primary endpoint (major car-
diovascular events) according to treatment in the multiple-country trial,
Justification for the Use of Statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin (JUPITER) (2003–2008), before (A) and after
standardizing to the imputed cohort (B) and the complete case cohort
(C), with selection weight truncated at 20 and accounting for competing
risk of any death. The cumulative incidence curves were plotted based
on 20 imputed data sets (solid line for rosuvastatin group and dashed
line for placebo group).
characteristics between the complete case cohort and the JUPI-
TER trial participants. The JUPITER trial participants were 
more likely to be older and male, to have lower hs-CRP and 
lipid levels, and to receive aspirin, but were less likely to 
receive antihypertensive drugs.
The hazard ratio for the effect of rosuvastatin initiation on pri-
mary CVD prevention was 0.56 (95% confidence interval (CI): 
0.46, 0.69) based on the intention-to-treat analysis in JUPITER 
(2), and it was attenuated to 0.74 (95% CI: 0.45, 1.25) after 
weighting to the imputed cohort. We estimated a hazard ratio of 
0.71 (95% CI: 0.45, 1.11) after truncating the selection weights 
at 20 (Figure 1). After weighting the trial participants to the 
complete case cohort, the hazard ratio of the rosuvastatin effect 
was 0.71 (95% CI: 0.46, 1.10), which was similar to the estimate 
obtained by weighting to the imputed cohort, despite the differ-
ences in characteristics between the two cohorts. The hazard 
ratio remained 0.68 (95% CI: 0.45, 1.03) with weight truncated 
at 20. In a test for interaction between treatment and follow-up 
time, there was no clear violation of the proportional hazards 
assumption in the JUPITER trial and after standardizing to the 
complete case cohort. However, the proportional hazards assump-
tion was violated in the JUPITER trial after standardizing to the 
imputed cohort due to a few patients in the placebo group who 
had large weights (>10) and developed CVD at approximately 3 
years. We still report the hazard ratio but also report cumulative 
incidences, which might be more valid in this setting.
Figure 2 and Table 4 show the plots and estimates of crude 
and weighted cumulative incidences of CVD events, respec-
tively. Rosuvastatin was associated with an absolute reduction 
in the cumulative incidence of CVD events of 3.3 percentage 
points (95% CI: 2.1, 4.5) at 4 years (Figure 2A). After weight-
ing to the imputed cohort, the benefits of rosuvastatin did not 
emerge until the end of 2 years of treatment (Figure 2B), but 
with 5.8 percentage points, the risk reduction was larger at 4 
years (95% CI: 1.0, 10.6). The trending of cumulative incidence 
was similar between the results of JUPITER (Figure 2A) and 
the results after standardizing to the complete case cohort 
(Figure 2C). The absolute reduction in the cumulative incidence 
of CVD events associated with rosuvastatin became overt at the 
end of the first year from randomization and was 3.7 percentage 
points (95% CI: 1.2, 6.2) at 4 years.
When generalizing trial results to patients aged younger than 
80 years in the imputed cohort (baseline characteristics are 
shown in Web Tables 1 and 2), the estimate of the rosuvastatin 
effects was stronger and more precise (hazard ratio = 0.55; 95%
CI: 0.40, 0.77, without applying weight truncation, Figure 3). 
The benefits of rosuvastatin became overt after the first year 
from randomization (Figure 4) and the risk reduction was 2.7 
percentage points (95% CI: 1.8, 3.6) at 4 years (Table 5). Stron-
ger benefits of rosuvastatin were also observed when generaliz-
ing to those aged <80 years in the complete case cohort (hazard 
ratio = 0.61; 95% CI: 0.42, 0.88, without applying weight trun-
cation). Similar trending of cumulative incidence were observed 
with 2.9 percentage points (95% CI: 0.6, 5.3) at 4 years.
DISCUSSION
In this study, we showed that generalizing the JUPITER trial 
results to the UK target population who would have been
key inclusion criteria were available only in a selected subgroup
of the target population.We addressed this selection problem by
imputing missing values. We found that only a very small pro-
portion of the CPRD patients had complete data on all relevant
clinical variables, and that the imputed cohort and complete
case cohort were quite different. The results indicated that
selection of study populations without accounting for missing-
ness on effect modifiers would fail to represent the target pop-
ulation from the real world.
Approaches dealing with missing data on confounders in
nonexperimental studies have been extensively investigated
with respect to bias (20, 21). Common methods such as com-
plete case analysis and use of missing indicators have been
shown to yield biased estimates in realistic settings. In contrast,
multiple-imputation methods lead to unbiased estimates under
a more plausible assumption, the missing-at-random assump-
tion. While confounding control is not exactly the same as gen-
eralizability, the methods to deal with missing values are likely
Table 4. Risk Difference of Major Cardiovascular Events for Rosuvastatin in “Justification for the Use of Statins in
Prevention: an Intervention Trial Evaluating Rosuvastatin” (Multiple Countries, 2003–2008), Before and After
Standardizing to the Imputed Cohort and the Complete Case Cohort From the Clinical Practice Research Datalink
(United Kingdom, 2001–2014), with SelectionWeight Truncated at 20
Year From
Randomization
JUPITER JUPITER, Standardized to theImputed Cohort
JUPITER, Standardized to the
Complete Case Cohort
Risk Difference, % 95%CI Risk Difference, % 95%CI Risk Difference, % 95%CI
1 −0.5 −0.7,−0.2 0.2 −0.5, 0.9 −0.4 −1.0, 0.2
2 −1.0 −1.5,−0.6 −0.3 −1.3, 0.8 −0.4 −1.6, 0.7
3 −2.0 −2.9,−1.1 −2.7 −5.8, 0.4 −1.7 −3.5, 0.1
4 −3.3 −4.5,−2.1 −5.8 −10.6,−1.0 −3.7 −6.2,−1.2
Abbreviation: CI, confidence interval; JUPITER, Justification for the Use of Statins in Prevention: an Intervention
Trial Evaluating Rosuvastatin.
0.3 0.5 1.0 1.5 2.0
Crude
Standardized to Imputed Cohort
Standardized to Complete Case Cohort
Untruncated Weights
Untruncated Weights
Weights Truncated at 50
Weights Truncated at 40
Weights Truncated at 30
Weights Truncated at 20
Weights Truncated at 10
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Weights Truncated at 40
Weights Truncated at 30
Weights Truncated at 20
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Figure 3. Treatment effect (hazard ratio (HR) and 95% confidence interval (CI)) of rosuvastatin in the multiple-country trial, Justification for the Use
of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) (2003–2008), before and after standardizing to the complete case
cohort and complete case cohort among patients aged <80 years without selection weight truncation. For the results from JUPITER standardized to
the imputed cohort, the hazard ratios were first estimated in JUPITER standardized to each imputed data set (Web Table 9) and then combined into
overall estimates to account for variability.
to share many characteristics across these settings. In our study,
the missing-at-random assumption is likely violated to some
extent for many factors, but it seemed plausible for routine lab-
oratory tests and a measure of subclinical inflammation (i.e.,
hsCRP) in our setting. Previous studies of the UK primary care
databases have suggested that BMI and blood pressure mea-
surements were likely missing at random, and that prevalence
of current smoking was similar to that observed in the national
survey (22–24). In addition, our study examined the older
population who were free of major diseases (i.e., diabetes,
CVD, and cancer). Among these relatively healthy older
patients, laboratory tests may be more likely to be part of their
routine examinations rather than due to anticipated abnormali-
ties. Patients who were older or visited general practice more
regularly may be more likely to receive routine examinations.
The prediction of missing data based on measured patient char-
acteristics varied widely, and more work is needed to identify
situations where multiple imputation will not work. Multiple
imputation has been shown to be useful, however, even in set-
tings with modest prediction (25).
Weighing by inverse probability of missingness is an alterna-
tive approach to dealing with missing data; however, standard
applications require a monotone missing pattern when there are
multiple missing variables (26, 27), which was not the case in
our data. We therefore implemented a simplified version of
weighting as a secondary analysis. To bypass the assumption of
monotone missingness, we created an overall missing indi-
cator and reweighted the complete case population to the entire
eligible population (WebAppendix 2). The results were similar
to the results after standardizing to the complete case cohort.
The effect of rosuvastatin on primary prevention of CVD
became attenuated after standardizing the trial results to the
imputed or complete case cohort. This shift toward the null can
be explained in part by more subjects aged≥80 years and high-
er values of hs-CRP andHDL-C in the target population. Greater
benefits of rosuvastatin on the relative-risk scale were observed
in the JUPITER trial for patients with HDL-C ≤50 mg/dL than
for those with HDL-C >50 mg/dL (hazard ratio = 0.50 vs. 0.73)
and those with lower hs-CRP values at baseline (≤3.5 mg/L)




Figure 4. Cumulative incidences of the primary endpoint (major car-
diovascular events) according to treatment in the multiple-country
trial, Justification for the Use of Statins in Prevention: an Intervention
Trial Evaluating Rosuvastatin (JUPITER) (2003–2008), before (A)
and after standardizing to the imputed cohort (B) and the complete
case cohort (C) among patients aged <80 years without selection
weight truncation and with accounting for competing risk of any death.
The cumulative incidence curves were plotted based on 20 imputed
data sets (solid line for rosuvastatin group and dashed line for placebo
group).
Table 5. Risk Difference of Major Cardiovascular Events for Rosuvastatin Among Patients Aged Less Than 80
Years in “Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin” (Multiple
Countries, 2003–2008), Before and After Standardizing to the Imputed Cohort and the Complete Case Cohort From
the Clinical Practice Research Datalink (United Kingdom, 2001–2014), without SelectionWeight Truncation
Year From
Randomization
JUPITER JUPITER, Standardized to theImputed Cohort
JUPITER, Standardized to the
Complete Case Cohort
Risk Difference, % 95%CI Risk Difference, % 95%CI Risk Difference, % 95%CI
1 −0.5 −0.8,−0.3 −0.5 −0.8,−0.2 −0.4 −1.0, 0.1
2 −1.1 −1.5,−0.6 −0.9 −1.3,−0.5 −0.8 −1.6,−0.1
3 −2.0 −2.8,−1.1 −1.7 −2.8,−0.6 −1.9 −3.5,−0.3
4 −2.8 −4.1,−1.6 −2.7 −3.6,−1.8 −2.9 −5.3,−0.6
Abbreviation: CI, confidence interval; JUPITER, Justification for the Use of Statins in Prevention: an Intervention
Trial Evaluating Rosuvastatin.
levels (hazard ratio = 0.38 vs. 0.80 vs. 0.65), although these
differences were not statistically significant. However, only
806 JUPITER participants were aged 80 years or older (Web
Table 3), leading to an imprecise estimate of the treatment
effect in this subgroup and limiting our ability to generalize the
trial results to patients in that age group in the target population.
Thus, we also generalized the trial results to those aged <80
years in the target population and found greater benefits of
rosuvastatin in those relatively younger population.
We also observed a rosuvastatin effect on primary CVD
prevention on the risk-difference scale after generalizing to
the imputed cohort and complete case cohort (Figure 2 and
Table 4). The JUPITER trial results and the results reweighted
to the complete case cohort showed the effect of rosuvastatin
on CVD prevention following the first year from randomi-
zation. In contrast, the risk reduction associated with rosu-
vastatin in the JUPITER trial generalized to the imputed
cohort was not observed until the end of the second year from
randomization and abruptly increased after 3 years. This is
because the large increases in the cumulative incidence after
2.5 years of follow-up were observed only in the placebo
group, resulting from a few patients who were over the age of
80 years with some less-prevalent characteristics (e.g., nonuse
of aspirin and any antihypertensive drugs or higher HDL-C
levels), and thus had large weights and also had incident cardio-
vascular disease. This pattern—that the rosuvastatin benefits on
CVD were strong only after prolonged treatment—was also
seen among patients aged ≥80 years in the original (i.e.,
unweighted) JUPITER trial but not for patients aged <70,
70–74, and 75–79 years (Web Figure 4). In addition, when gen-
eralizing the trial results to the patients aged <80 years in the
imputed cohort, the rosuvastatin effects also emerged at 1 year.
Our study has a number of limitations. We need to consider
the validity of the assumption that we captured all characteris-
tics related to selection into the trial and to treatment effect het-
erogeneity. This assumption is analogous to the assumption of
no unmeasured confounding when estimating treatment effects
in a nonexperimental study (7). The CPRD includes a variety of
data, allowing us to identify potential variables as comprehen-
sively as possible; however, owing to the inherent limitations of
the CPRD, race/ethnicity is not available. The JUPITER trial
enrolled patients from various racial/ethnic groups and from 26
countries. It is possible that both factors would affect the proba-
bility of selection into the trial. Although race/ethnicity has
been shown to affect LDL-C responses to statin treatment (28),
the subgroup analysis of the JUPITER trial showed no differ-
ence of racial/ethnic groups and regions on the treatment effect
of rosuvastatin. Thus, the assumption of “no unmeasured effect
modifiers” might still be plausible in this setting. We also
assumed that we correctly specified the logistic models used
to predict the probability of selection, although the true mod-
els are unknown. The weighted results could be sensitive to
the model specification. In this study, we tested the selection
models by examining marginal balance of covariates. In the
future, more flexible methods, such as a generalized additive
model or machine learning, may help relax this assumption of
model specification. In addition, our generalized results were lim-
ited within the CPRD population to patients who would have
been eligible for JUPITER. The JUPITER results cannot be gen-
eralized to subjects who are not represented in JUPITER due
to the positivity assumption.Althoughwe selected the target pop-
ulation strictly following the inclusion/exclusion criteria of JUPI-
TER, there is a possibility of some violation of the positivity
assumption. Despite the lack of an upper age limit in JUPITER,
the oldest trial participant was 97 years of age, making it impossi-
ble to generalize trial results to patients older than that. Last,
our estimate of the rosuvastatin effect on CVD after generaliz-
ing to the imputed cohort was very imprecise due to large
weights in some patients. We applied weight truncation to
increase the precision of the treatment effect estimate, but
it made the weighted trial population slightly less representa-
tive of the target population. Despite these limitations, this
generalization method based on weighting can still be an effec-
tive solution to translate the results of an RCT to real-world
population.
In summary, after addressing selection into the JUPITER
trial, the relative treatment effect of rosuvastatin on CVD events
generalized to the UK target population eligible to enroll the
JUPITER trial was slightly less pronounced but still present,
especially with prolonged duration of treatment. Our study
found that only a small fraction of the eligible CPRD patients
had complete data on all effect modifiers and provides evidence
for the need to impute missing data when generalizing trial re-
sults to target populations.
ACKNOWLEDGMENTS
Author affiliations: Department of Epidemiology, Gillings
School of Global Public Health, University of North Carolina
at Chapel Hill, Chapel Hill, North Carolina (Jin-Liern Hong,
Michele Jonsson Funk, Stephen R. Cole, MichaelWebster-
Clark, Jessie K. Edwards, Til Stürmer); Medical Evidence and
Observational Research, AstraZeneca Pharmaceuticals,
Gaithersburg,Maryland (Robert LoCasale); and R&D
Information, AstraZeneca Pharmaceuticals, Waltham,
Massachusetts (Sara E. Dempster).
This work was supported by AstraZeneca. T.S. is
supported by the National Institutes of Health (grants R01/
R56 AG023178, AG056479, R01 CA174453, R01
HL118255, R01MD011680, and R21-HD080214). M.J.F.
is supported by the National Institutes of Health (grants R01
HL118255, R01 AG023178, and AG056479) and the
Reagan Udall Foundation. S.R.C. is supported in part
through the National Institutes of Health (grants R01
AI100654, R24 AI067039, U01 AI103390, P30 AI050410,
and DP2 HD084070).
Portions of this paper were presented at the 32nd Annual
Meeting of the International Society for
Pharmacoepidemiology, Dublin, Ireland, August 25–28, 2016
R.L. and S.E.D. were employees of AstraZeneca at the time
of the study. T.S. andM.J.F. do not accept personal
compensation of any kind from any pharmaceutical company,
although they receive salary support from the Center for
Pharmacoepidemiology in the Department of Epidemiology,
Gillings School of Global Public Health (current members:
GlaxoSmithKline, UCBBioSciences, Merck, and Shire). T.S.
owns stock in Novartis, Roche, BASF, AstraZeneca, and
NovoNordisk. The other authors report no conflicts.
REFERENCES
1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/
AHA guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults: a report of the
American College of Cardiology/American Heart Association
Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;
63(25 Pt B):2889–2934.
2. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to
prevent vascular events in men and women with elevated C-
reactive protein. N Engl J Med. 2008;359(21):2195–2207.
3. Kappagoda CT, Amsterdam EA. Another look at the results of
the JUPITER trial. Am J Cardiol. 2009;104(11):1603–1605.
4. Glynn RJ, KoenigW, Nordestgaard BG, et al. Rosuvastatin for
primary prevention in older persons with elevated C-reactive
protein and low to average low-density lipoprotein cholesterol
levels: exploratory analysis of a randomized trial. Ann Intern
Med. 2010;152(8):488–496.
5. Ridker PM,MacFadyen J, CressmanM, et al. Efficacy of
rosuvastatin amongmen and womenwith moderate chronic
kidney disease and elevated high-sensitivity C-reactive protein:
a secondary analysis from the JUPITER (Justification for the
Use of Statins in Prevention-an Intervention Trial Evaluating
Rosuvastatin) trial. J AmColl Cardiol. 2010;55(12):1266–1273.
6. Ridker PM,MacFadyen JG, Fonseca FA, et al. Number needed
to treat with rosuvastatin to prevent first cardiovascular events
and death among men and women with low low-density
lipoprotein cholesterol and elevated high-sensitivity C-reactive
protein: justification for the use of statins in prevention: an
intervention trial evaluating rosuvastatin (JUPITER). Circ
Cardiovasc Qual Outcomes. 2009;2(6):616–623.
7. Cole SR, Stuart EA. Generalizing evidence from randomized
clinical trials to target populations: the ACTG 320 trial. Am J
Epidemiol. 2010;172(1):107–115.
8. Rosenbaum PR, Rubin DB. The central role of the propensity
score in observational studies for causal effects. Biometrika.
1983;70(1):41–55.
9. Sato T, Matsuyama Y. Marginal structural models as a tool for
standardization. Epidemiology. 2003;14(6):680–686.
10. The Clinical Practice Research Datalink (CPRD). https://www.
cprd.com/home/. Accessed November 15, 2016.
11. Rubin DB, Schenker N. Multiple imputation in health-care
databases: an overview and some applications. Stat Med. 1991;
10(4):585–598.
12. Schemper M, Smith TL. Efficient evaluation of treatment
effects in the presence of missing covariate values. Stat Med.
1990;9(7):777–784.
13. Schemper M, Heinze G. Probability imputation revisited for
prognostic factor studies. Stat Med. 1997;16(1–3):73–80.
14. Rubin DB.Multiple Imputation for Nonresponse in Surveys.
New York, NY: JohnWiley & Sons; 2004.
15. Little RJ. Regression with missing X’s: a review. J Am Stat
Assoc. 1992;87(420):1227–1237.
16. Cole SR, Lau B, Eron JJ, et al. Estimation of the standardized risk
difference and ratio in a competing risks framework: application
to injection drug use and progression to AIDS after initiation of
antiretroviral therapy. Am J Epidemiol. 2015;181(4):238–245.
17. Cole SR,HernánMA.Constructing inverse probabilityweights for
marginal structuralmodels.AmJEpidemiol. 2008;168(6):656–664.
18. Stürmer T, Joshi M, Glynn RJ, et al. A review of the
application of propensity score methods yielded increasing use,
advantages in specific settings, but not substantially different
estimates compared with conventional multivariable methods.
J Clin Epidemiol. 2006;59(5):437–447.
19. Stürmer T, Rothman KJ, Avorn J, et al. Treatment effects in
the presence of unmeasured confounding: dealing with
observations in the tails of the propensity score
distribution–a simulation study. Am J Epidemiol. 2010;
172(7):843–854.
20. VachW, Blettner M. Biased estimation of the odds ratio in
case-control studies due to the use of ad hoc methods of
correcting for missing values for confounding variables. Am J
Epidemiol. 1991;134(8):895–907.
21. Greenland S, FinkleWD. A critical look at methods for
handling missing covariates in epidemiologic regression
analyses. Am J Epidemiol. 1995;142(12):1255–1264.
22. Bhaskaran K, Forbes HJ, Douglas I, et al. Representativeness
and optimal use of body mass index (BMI) in the UK Clinical
Practice Research Datalink (CPRD). BMJ Open. 2013;3(9):
e003389.
23. Booth HP, Prevost AT, Gulliford MC. Validity of smoking
prevalence estimates from primary care electronic health
records compared with national population survey data for
England, 2007 to 2011. Pharmacoepidemiol Drug Saf. 2013;
22(12):1357–1361.
24. Marston L, Carpenter JR, Walters KR, et al. Issues in multiple
imputation of missing data for large general practice clinical
databases. Pharmacoepidemiol Drug Saf. 2010;19(6):
618–626.
25. Rubin DB. Multiple imputation after 18+ years. J Am Stat
Assoc. 1996;91(434):473–489.
26. Tsiatis AA. Semiparametric Theory andMissing Data. New
York, NY: Springer; 2006.
27. Horton NJ, Kleinman KP. Much ado about nothing: a
comparison of missing data methods and software to fit
incomplete data regression models. Am Stat. 2007;61(1):
79–90.
28. YoodMU,McCarthy BD, Kempf J, et al. Racial differences in
reaching target low-density lipoprotein goal among individuals
treated with prescription statin therapy. AmHeart J. 2006;
152(4):777–784.
29. Yang D, Dalton JE. A Unified Approach to Measuring the
Effect Size Between Two Groups Using SAS. http://support.
sas.com/resources/papers/proceedings12/335-2012.pdf.
Accessed November 15, 2016.
